This is the authors' abstract. We don't add key points for this paper.
Introduction: Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients are characterized by poor prognosis. Copanlisib is a pan-Class I phosphatidylinositol 3-kinase (PI3K) inhibitor, with modest single-agent activity in unselected DLBCL patients. Here we report the treatment effect of copanlisib in relapsed/refractory DLBCL patients with regards to cell of origin (COO) and molecular biomarker profiles (NCT02391116). Methods: Patients with relapsed/refractory DLBCL and ≥1 prior lines of therapy were eligible. Copanlisib (60 mg IV infusion) was administered intermittently on days 1, 8 and 15 of a 28-day cycle. Tumor samples were evaluated for COO, CD79B mutations and >400 genes by next generation sequencing (NGS). The primary endpoint was objective tumor response rate (ORR; per Lugano Classification, 2014) and response by COO and CD79B status. Results: The full-analysis (FAS) and per-protocol sets (PPS; ≥3 doses, post-baseline scans and COO/CD79B data) included 67 and 40 patients, respectively. Patients were 58% male, median age 69 (range 25-93), ECOG status 0/1/2 22%/57%/21%, and heavily pretreated (median prior lines = 3, range 1-13). In the PPS, COO (and mutant CD79B status) analysis identified 22 GCB DLBCL (2 mutant), 16 ABC DLBCL (6 mutant), and 2 unclassifiable. The ORR in the FAS was 19% (13 of 67). For patients in the PPS, the ORR was 25% (10 of 40), with 5 complete responses (CR) and 5 partial responses (PR); stable disease in 12 pts. The ORR was 13.6% with 1 CR in GCB pts and 37.5% with 4 CRs (25%) in ABC patient. Response to copanlisib was 25% in pts with (2/8) and without (8/32) CD79B mutations. Five of 10 ABC DLBCL-wild-typeCD79B patients and one GCB DLBCL-mutantCD79B responded (ongoing >17 cycles). NGS analysis in 54 patients detected 348 mutations; BCL2 (54% of patients), TP53 (41%), BCL6 (30%), MYC (22%), CD79B (19%)/A (6%), MYD88 (19%), TNFAIP3 (17%), CARD11 (13%), and NFKBIA (9%). Response to copanlisib was not significantly different based on mutation status of BCL2 (ORR 17% [4/24] vs 35% [7/20] for mutant and wild-type subsets, respectively), BCL6 (ORR 17% [2/12] vs 28% [9/32]), MYC (ORR 13% [1/8] vs 28% [10/36]), and MYD88 (ORR 25% [2/8] vs 25% [9/36]). With a median of 6 cycles (range 1-29), the most common AEs (% all grade/gr3 + 4) were diarrhea (36/2), nausea (31/2), fatigue (31/3), fever (21/2) and transient hypertension (40/33) and hyperglycemia (34/31). There were 14 grade 5 AEs (none drug-related).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lenz et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: